MTSR חוב כולל להון Metsera Therapeutics

The current share price of Metsera Inc (MTSR) plotted on this chart demonstrates a debt-to-equity ratio of 0.01. The operating model relies on external contractors for the production of biologics, which is offset by strict quality oversight. Management's strategy focuses on developing convenient, long-acting medications. Consequently, Metsera Inc (MTSR) is creating innovative peptide therapies capable of transforming the approach to obesity treatment.

This indicator is calculated as the ratio of total liabilities to the market value of equity, measuring the business's degree of reliance on debt financing. On the GURU.Markets platform, the total debt-to-equity ratio allows for an assessment of the financial stability of Metsera Inc. (MTSR) amid a lack of revenue and high costs associated with the final stages of clinical drug trials.